Patients who remained on the oral PCSK9 inhibitor enlicitide decanoate throughout two large Phase 3 trials achieved LDL cholesterol reductions of approximately 64% at six

More than one in four patients with treatment-resistant high blood pressure have abnormally elevated cortisol levels that may be contributing to their failure to respond

New ACC/AHA Guideline Overhauls Cholesterol Management with Earlier Intervention and Tighter Treatment Targets The American College of Cardiology and the American Heart Association today released

Young adults who spend six or more hours a day on screens outside of school or work show significantly worse blood pressure, cholesterol levels and

Deaths from heart disease linked to high blood pressure among young women have risen more than fourfold over the past two decades, according to striking

Measures of blood vessel health derived from routine blood pressure readings could help identify adults at heightened risk for dementia, according to new research unveiled

Ez-PAVE trial: aiming for LDL-C below 55 mg/dL rather than 70 mg/dL reduces major cardiovascular events by 33% in patients with atherosclerotic cardiovascular disease, providing

CHAMPION-AF trial: Left atrial appendage closure proves non-inferior to NOACs for stroke, cardiovascular death and embolism at three years, while cutting non-procedural bleeding rates nearly

VESALIUS-CV subanalysis: evolocumab reduces major adverse cardiac events by 31% in patients with diabetes but no known atherosclerosis, potentially redefining the role of PCSK9 inhibitors

Phase 2 trial of tonlamarsen in resistant hypertension: the drug’s unexpectedly prolonged action confounds interpretation of results, raising new questions about how much angiotensinogen suppression